Method of ultrasonically quantitating myocardial perfusion using as intravenously injected tracer
First Claim
Patent Images
1. A method of quantitatively measuring blood flow in the myocardium of a patient comprising:
- (a) initiating ultrasonic imaging of the myocardium;
(b) while said imaging is continued, intravenously injecting an effective dosage of a suspension of biocompatible tracer microspheres containing an insoluble gas into the patient, wherein;
(i) the microspheres have a mean diameter that permits them to pass through the pulmonary capillaries of the patient and(ii) said suspension is capable of maintaining 25% of the initial optical density at 600 nm after being subjected to a pressure of 5 psi for 30 seconds;
(c) continuing said imaging during the first transit of the microspheres through the myocardium;
(d) determining a videodensity versus time relationship from the images obtained in steps (a) through (c); and
(e) calculating the blood flow in the myocardium from said relationship.
0 Assignments
0 Petitions
Accused Products
Abstract
Myocardial perfusion is assessed quantitatively by an ultrasonic echocardiographic procedure in which: the myocardium is ultrasonically imaged; an ultrasonic contrast agent consisting of a suspension of pressure-stable, water-insoluble gas-containing microspheres sized to pass through the pulmonary capillaries is injected intravenously; imaging is continued through the first transit of the microspheres through the myocardium; the videodensity versus time relationship is determined from the images; and blood flow through the myocardium is calculated from that relationship.
212 Citations
10 Claims
-
1. A method of quantitatively measuring blood flow in the myocardium of a patient comprising:
-
(a) initiating ultrasonic imaging of the myocardium; (b) while said imaging is continued, intravenously injecting an effective dosage of a suspension of biocompatible tracer microspheres containing an insoluble gas into the patient, wherein; (i) the microspheres have a mean diameter that permits them to pass through the pulmonary capillaries of the patient and (ii) said suspension is capable of maintaining 25% of the initial optical density at 600 nm after being subjected to a pressure of 5 psi for 30 seconds; (c) continuing said imaging during the first transit of the microspheres through the myocardium; (d) determining a videodensity versus time relationship from the images obtained in steps (a) through (c); and (e) calculating the blood flow in the myocardium from said relationship. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeMolecular Biosystems, Inc (Alliance Pharmaceutical Corporation)
-
Original AssigneeMolecular Biosystems, Inc (Alliance Pharmaceutical Corporation)
-
InventorsLevene, Harold B., Bales, Gary L., Widder, Kenneth J.
-
Primary Examiner(s)MANUEL, GEORGE C
-
Application NumberUS08/659,542Time in Patent Office664 DaysField of Search128/653.1, 128/653.4, 128/654, 128/662.02, 128/661.09, 128/661.1, 128/661.08US Class Current600/458CPC Class CodesA61B 8/06 Measuring blood flow measur...A61B 8/481 involving the use of contra...A61K 49/223 Microbubbles, hollow micros...
